Primary aim of this pilot study is to provide evidence for a non-invasive, continuous, and transcutaneous measurement method to determine blood glucose levels robustly and accurately.
The study is divided into 3 sub-studies focusing on * Interchangeability of Lab demo 1.0 * Evaluation of advanced spectroscopy methods and their miniaturisation potential * Robustness of machine learning model to changes over time
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
43
During the intervention, transcutaneous spectral data are collected continuously with the Lab demo. Up to 20 whole blood glucose reference values are also collected, as well as interstitial fluid glucose values using a continuous glucose monitoring device. Some participants will attend multiple measurement sessions.
Liom Health AG
Pfaeffikon, Canton of Schwyz, Switzerland
Comparison of glucose changes measured over a time series of transcutaneous measurements with reference measurements
The transcutaneous glucose measurements and the corresponding spectral fingerprints are compared with the values of interstitial fluid (ISF) and capillary blood glucose.
Time frame: The data is collected during the study procedure (up to 3 hours)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.